NRAS mutation status is an independent prognostic factor in metastatic melanoma - PubMed (original) (raw)

. 2012 Aug 15;118(16):4014-23.

doi: 10.1002/cncr.26724. Epub 2011 Dec 16.

Roland L Bassett Jr, Chaan S Ng, Jonathan L Curry, Richard W Joseph, Gladys C Alvarado, Michelle L Rohlfs, Jessie Richard, Jeffrey E Gershenwald, Kevin B Kim, Alexander J Lazar, Patrick Hwu, Michael A Davies

Affiliations

NRAS mutation status is an independent prognostic factor in metastatic melanoma

John A Jakob et al. Cancer. 2012.

Abstract

Background: There is a need for improved prognostic markers in melanoma. In this study, the authors tested the prognostic significance and clinicopathologic correlations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) mutations in patients with metastatic melanoma.

Methods: Clinical and pathologic data were collected retrospectively on melanoma patients who were clinically tested for BRAF (exon 15) and NRAS (exons 1 and 2) mutations at The University of Texas M. D. Anderson Cancer Center. Analyses were performed to identify significant associations of mutations with tumor and patient characteristics and with survival from the diagnosis of stage IV disease.

Results: The genotypes of the full cohort (n = 677) were 47% BRAF mutation, 20% NRAS mutation, and 32% wild-type for BRAF and NRAS ("WT"). Tumor mutation status was associated (P = .008) with the risk of central nervous system involvement at the diagnosis of stage IV disease, with a higher prevalence observed in BRAF-mutant (24%) and NRAS-mutant (23%) patients than in WT patients (12%). Among patients with nonuveal melanoma who underwent mutation testing within 6 months of stage IV diagnosis (n = 313), patients with NRAS mutations had a median survival of 8.2 months from stage IV diagnosis, which was shorter than the median survival of WT patients (15.1 months; P = .004). Multivariate analysis of this population incorporating age, sex, metastases (M1) category, serum lactate dehydrogenase level, and mutation status confirmed that NRAS mutations are associated independently with decreased overall survival (vs WT; P = .005; hazard ratio, 2.05).

Conclusions: Patients with BRAF or NRAS mutations were more likely than WT patients to have central nervous system involvement at the time they were diagnosed with distant metastatic disease. NRAS mutation status was identified as an independent predictor of shorter survival after a diagnosis of stage IV melanoma.

Copyright © 2011 American Cancer Society.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Overall survival from the diagnosis of stage IV by BRAF and NRAS mutation status

Kaplan Meier analysis of survival from stage IV diagnosis for (A) all stage IV patients (n=519) and (B) non-uveal stage IV melanoma patients with molecular testing within 6 months of stage IV diagnosis (n=313). Green, WT patients; Red, NRAS patients; Blue, BRAF patients [in Panel (B), dashed line indicates outcomes in BRAF patients treated with a BRAF or MEK inhibitor (abbreviated BRAF w/i, BRAF w/inhibitor in figure); solid blue line, BRAF patients not treated with a BRAF or MEK inhibitor (abbreviated BRAF w/o i, BRAF w/o inhibitor in figure)].

Figure 1

Figure 1. Overall survival from the diagnosis of stage IV by BRAF and NRAS mutation status

Kaplan Meier analysis of survival from stage IV diagnosis for (A) all stage IV patients (n=519) and (B) non-uveal stage IV melanoma patients with molecular testing within 6 months of stage IV diagnosis (n=313). Green, WT patients; Red, NRAS patients; Blue, BRAF patients [in Panel (B), dashed line indicates outcomes in BRAF patients treated with a BRAF or MEK inhibitor (abbreviated BRAF w/i, BRAF w/inhibitor in figure); solid blue line, BRAF patients not treated with a BRAF or MEK inhibitor (abbreviated BRAF w/o i, BRAF w/o inhibitor in figure)].

Figure 2

Figure 2. Overall survival from the diagnosis of stage IV by BRAF and NRAS mutation status in patients without CNS involvement at the diagnosis of stage IV disease

Kaplan-Meier analysis of survival from stage IV among non-uveal metastatic melanoma patients with molecular testing within 6 months of stage IV diagnosis who did not have CNS involvement at stage IV presentation (n=240). Green, WT patients; Red, NRAS patients; Blue, BRAF patients [dashed line indicates outcomes in BRAF patients treated with a BRAF or MEK inhibitor (abbreviated BRAF w/i, BRAF w/inhibitor in figure); solid blue line, BRAF patients not treated with a BRAF or MEK inhibitor (abbreviated BRAF w/o i, BRAF w/o inhibitor in figure)].

Similar articles

Cited by

References

    1. American Cancer Society. Cancer Facts and Figures 2011. Atlanta, Georgia: American Cancer Society; 2011.
    1. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–34. - PubMed
    1. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635–48. - PubMed
    1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206. - PMC - PubMed
    1. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011;164(4):776–84. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources